安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- ASCO Treatment Guidelines for HER2-Negative Metastatic Breast Cancer . . .
Dr Beverly Moy Key Points An ASCO Expert Panel has updated the treatment guidelines on chemotherapy and targeted therapy for patients with HER2-negative metastatic breast cancer to include trastuzumab deruxtecan as a treatment option based on the survival benefits observed in the DESTINY-Breast04 trial
- Updates to the Management of HR-Positive, HER2-Negative Breast Cancer . . .
Metastatic hormone receptor–positive, HER2-negative breast cancer treatment is increasingly individualized as more of the tumor landscape is described and targeted therapies are developed CDK4 6 inhibitors have demonstrated consistency in prolonging progression-free survival across several clinical trials in advanced disease Research in endocrine therapy highlighted the noninferiority of
- Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO . . .
A 2010-2012 retrospective cohort with data from 3,231 women in the National Cancer Database with HER2-positive MBC compared those who did and did not undergo definitive breast surgery showed surgery was associated with a 44% reduction in the risk of death 48 In addition, a recent systematic review and meta-analysis showed benefit in patients
- Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast . . .
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center The treatment included a histone deacetylase (HDAC) inhibitor — a drug that causes a chemical change to stop tumor cells from dividing — with two types of immunotherapy known as
- Treatment for HER2-Negative Advanced Breast Cancer - WebMD
When you have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on managing your disease, not curing the cancer The goal is to help you live longer and have a better
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast . . .
Among patients with metastatic hormone receptor–positive, HER2-negative breast cancer, real-world data show short progression-free survival after CDK4 6 inhibitor therapy, when serial single
- Targeting HER2-low in metastatic breast cancer: an evolving treatment . . .
The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer In this trial, T-DXd was associated with a substantial survival benefit among patients with hormone receptor
- Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current . . .
In the treatment of hormone-receptor positive, HER2 negative metastatic breast cancer, targeted therapy showed improved overall survival and it has become an established treatment within recent years Some study results conflict with others As
|
|
|